Clinical Trials Browser

Phase 2 × Neoplasms × Crizotinib × Clear all

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT01945021 2021-02-21

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Phase 2 Completed

129 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms